Back to results
US 12,552,855 B2Granted
CD33 targeted immunotherapies
AssigneesRegeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
InventorsJordan Jarjour, Mark Pogson, Wai-Hang Leung, Kyle Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
Life of this patent
Estimating the term…
Abstract
The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Claims9
A polypeptide complex comprising:
- (a) a first polypeptide comprising:
- (i) an FRB multimerization domain polypeptide;
- (ii) a CD8α transmembrane domain or a CD4 transmembrane domain;
- (iii) a CD137 co-stimulatory domain;
- and/or
- (iv) a CD3ζ primary signaling domain;
- and
- (b) a second polypeptide comprising:
- (i) an anti-CD33 VHH antibody that has an amino acid sequence set forth in SEQ ID NO:
- 10;
- (ii) an FKBP12 multimerization domain polypeptide;
- and
- (iii) a CD4 transmembrane domain;
- wherein the second polypeptide comprises the sequence set forth in SEQ ID NO:
- 30.
12 more elements
Dependencies are inferred from the claim text.